A Phase I/II Trial of the Insulin-Like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in Patients With Embryonal and Alveolar Rhabdomyosarcoma
Phase of Trial: Phase I/II
Latest Information Update: 10 Sep 2018
At a glance
- Drugs Dasatinib (Primary) ; Ganitumab (Primary)
- Indications Rhabdomyosarcoma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 19 Dec 2017 Planned primary completion date changed from 1 Jan 2021 to 31 Oct 2021.
- 25 Feb 2017 Status changed from not yet recruiting to recruiting.